PMID- 25727011
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20220408
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 459
IP  - 3
DP  - 2015 Apr 10
TI  - Interleukin-18 enhances breast cancer cell migration via down-regulation of 
      claudin-12 and induction of the p38 MAPK pathway.
PG  - 379-86
LID - S0006-291X(15)00348-4 [pii]
LID - 10.1016/j.bbrc.2015.02.108 [doi]
AB  - Interleukin-18 (IL-18) was recently reported to have a pro-tumor effect in 
      various cancers. Increased IL-18 levels in the serum of cancer patients 
      correlated with malignancy, and IL-18 acts a crucial factor for cell migration in 
      gastric cancer and melanoma. Claudins, which are the most important tight 
      junction proteins, are also linked with cancer progression and metastasis. 
      However, the relationship between claudins and IL-18 is not well-understood. 
      Here, we show that the migratory ability of MCF-7 cells was reduced when 
      endogenous IL-18 expression was inhibited with IL-18 siRNA. Moreover, exogenous 
      IL-18 enhanced breast cancer cell migration and suppressed the expression of the 
      tight junction proteins claudin-1, claudin-3, claudin-4, and claudin-12 in MCF-7 
      cells. Knockdown of claudin-3, claudin-4, and claudin-12, but not claudin-1, 
      increased breast cancer migration with maximal effects observed in claudin-12 
      siRNA-transfected cells. To investigate whether the mitogen-activated protein 
      kinase (MAPK) signaling pathway is involved in IL-18-induced cell migration and 
      claudin-12 expression, cells were pretreated with SB203580 (an inhibitor of p38 
      MAPK) or PD98059 (an inhibitor of ERK1/2) prior to the addition of IL-18. 
      Although pretreatment of MCF-7 cells with SB203580 blocked both the enhanced cell 
      migration and the decreased claudin-12 expression, PD98059 only blocked cell 
      migration and did not affect claudin-12 expression. In addition, exogenous IL-18 
      induced rapid phosphorylation of p38 MAPK. These results suggest that IL-18 is an 
      important factor inducing breast cancer cell migration through down-regulation of 
      claudin-12 and activation of the p38 MAPK pathway.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Yang, Yoolhee
AU  - Yang Y
AD  - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Republic of Korea.
FAU - Cheon, Soyoung
AU  - Cheon S
AD  - Department of Life Science, Sookmyung Women's University, Seoul, Republic of 
      Korea.
FAU - Jung, Min Kyung
AU  - Jung MK
AD  - Department of Life Science, Sookmyung Women's University, Seoul, Republic of 
      Korea.
FAU - Song, Seok Bean
AU  - Song SB
AD  - Department of Life Science, Sookmyung Women's University, Seoul, Republic of 
      Korea.
FAU - Kim, Daejin
AU  - Kim D
AD  - Department of Anatomy, College of Medicine, Chung Ang University, Seoul, Republic 
      of Korea.
FAU - Kim, Hee Jung
AU  - Kim HJ
AD  - Department of Dermatology, St Mary's Hospital, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Park, Hyunjeong
AU  - Park H
AD  - Department of Dermatology, St Mary's Hospital, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Bang, Sa Ik
AU  - Bang SI
AD  - Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Republic of Korea. Electronic address: 
      si55.bang@samsung.com.
FAU - Cho, Daeho
AU  - Cho D
AD  - Department of Life Science, Sookmyung Women's University, Seoul, Republic of 
      Korea. Electronic address: cdhkor@sookmyung.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150227
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (CLDN1 protein, human)
RN  - 0 (CLDN12 protein, human)
RN  - 0 (CLDN3 protein, human)
RN  - 0 (CLDN4 protein, human)
RN  - 0 (Claudin-1)
RN  - 0 (Claudin-3)
RN  - 0 (Claudin-4)
RN  - 0 (Claudins)
RN  - 0 (Flavonoids)
RN  - 0 (Imidazoles)
RN  - 0 (Interleukin-18)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Recombinant Proteins)
RN  - OU13V1EYWQ (SB 203580)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
MH  - Breast Neoplasms/genetics/*pathology/*physiopathology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects/genetics/physiology
MH  - Claudin-1/antagonists & inhibitors/genetics/physiology
MH  - Claudin-3/antagonists & inhibitors/genetics/physiology
MH  - Claudin-4/antagonists & inhibitors/genetics/physiology
MH  - Claudins/antagonists & inhibitors/genetics/*physiology
MH  - Down-Regulation/drug effects
MH  - Female
MH  - Flavonoids/pharmacology
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Interleukin-18/antagonists & inhibitors/genetics/*physiology
MH  - *MAP Kinase Signaling System/drug effects
MH  - MCF-7 Cells
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Pyridines/pharmacology
MH  - RNA, Small Interfering/genetics
MH  - Recombinant Proteins/pharmacology
MH  - Tight Junctions/drug effects/physiology
OTO - NOTNLM
OT  - Breast cancer
OT  - Claudin-12
OT  - Interleukin-18 (IL-18)
OT  - Migration
OT  - Tight junction
EDAT- 2015/03/03 06:00
MHDA- 2015/06/24 06:00
CRDT- 2015/03/03 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2015/02/19 00:00 [accepted]
PHST- 2015/03/03 06:00 [entrez]
PHST- 2015/03/03 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S0006-291X(15)00348-4 [pii]
AID - 10.1016/j.bbrc.2015.02.108 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2015 Apr 10;459(3):379-86. doi: 
      10.1016/j.bbrc.2015.02.108. Epub 2015 Feb 27.